Endothelial regulation of inflammation in trauma and hemorrhagic shock

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

Document text

Principal Investigator: Jessica  Cardenas
Organization: UNIVERSITY OF COLORADO DENVER
Fiscal Year: 2024
Award: $390,000
Funding agency: National Institute of General Medical Sciences

Complications that arise secondary to an exaggerated innate immune response, such as multiple organ failure,
are a major cause of late-stage mortality in trauma patients. My overall goal is to initiate an innovative and
translational research program focused on elucidating mechanisms through which the vascular endothelium
regulates the host inflammatory response to severe trauma. In particular, my research is focused on the
immunomodulatory functions of the antithrombin (AT)-heparan sulfate system. AT elicits anti-inflammatory
signaling upon binding to specific heparan sulfate proteoglycan (HSPG) receptors on the endothelial surface that
contain a 3-0-sulfate (3-0S) modification. Our ongoing experiments demonstrate that dysregulation of the ATHSPG
system is a novel mechanism driving inflammation and organ injury following severe trauma and
hemorrhagic shock. However, the mechanisms that govern 3-0S HSPG expression and AT binding following
trauma is a major knowledge gap in the field. Understanding these mechanisms will enable us to develop novel
clinical tools to attenuate aberrant inflammation following trauma and treat or prevent subsequent organ failure.
The next 5 years of my proposed research program will focus on 3 developing programmatic areas that seek to
elucidate 1) mechanisms that mediate 3-0S HSPG degradation; 2) mechanisms that regulate 3-0S HSPG
biosynthesis; and 3) the biological role and therapeutic potential of unique AT variants capable of regulating
inflammation when 3-0S HSPG expression is reduced. Results of these investigations have broad-reaching
implications for many conditions in which inflammation contributes to the pathogenesis, such as sepsis,
transplantation, and COVID-19. Funding from this R35 award will 1) enable the establishment of my highly
innovative, long-term research program that is guided by the NIGMS mission; 2) advance our basic
understanding of the host inflammatory response to trauma; and 3) create novel therapeutics to improve longterm
survival and quality of life for the critically ill.

Terms: <Anabolism><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Area><Attenuated><Automobile Driving><Award><Binding><Biological><COVID-19><CV-19><Cell Communication and Signaling><Cell Signaling><Clinical><Coronavirus Infectious Disease 2019><Critical Illness><Critically Ill><Endothelial Cells><Endothelium><Funding><Goals><HSPG><Hemorrhagic Shock><Heparan Sulfate><Heparan Sulfate Proteoglycan><Heparitin Sulfate><Immune response><Immunological response><Immunomodulation><Inflammation><Inflammatory Response><Injury><Innate Immune Response><Intracellular Communication and Signaling><Investigation><Knowledge><MOF syndrome><Mediating><Mission><Modification><Molecular Interaction><Morbidity><Morbidity - disease rate><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><NIGMS><National Institute of General Medical Sciences><Organ><Organ failure><Pathogenesis><Proteoheparan Sulfate><QOL><Quality of life><Receptor Protein><Regulation><Research><Role><Secondary to><Sepsis><Signal Transduction><Signal Transduction Systems><Signaling><Sulfate><Surface><System><Therapeutic><Thrombase><Thrombin><Translational Research Enterprise><Transplantation><Trauma><Trauma patient><Traumatic injury><Variant><Variation><Vascular Endothelium><attenuate><attenuates><biologic><biological signal transduction><biosynthesis><blood infection><bloodstream infection><coronavirus disease 2019><coronavirus disease-19><coronavirus infectious disease-19><driving><endothelial dysfunction><experiment><experimental research><experimental study><experiments><fibrinogenase><host response><immune modulation><immune regulation><immune system response><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><improved><injuries><injury to organs><innovate><innovation><innovative><mortality><multiorgan failure><multiple organ system failure><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><organ injury><prevent><preventing><programs><receptor><social role><tool><translation research enterprise><translational research program><transplant><vascular contributions>